Trials / Completed
CompletedNCT03128593
A Study of JR-141 in Patients With Mucopolysaccharidosis Type II
A Phase I/II Study of JR-141 in Patients With Mucopolysaccharidosis Type II
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 14 (actual)
- Sponsor
- JCR Pharmaceuticals Co., Ltd. · Industry
- Sex
- Male
- Age
- 6 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study in patients with mucopolysaccharidosis type II (MPS II) is below, * to collect the safety information of JR-141 * to evaluate the plasma pharmacokinetics of JR-141 * to explore the efficacy of JR-141 on MPS II-related central nervous system symptoms and general symptoms
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | JR-141 | IV infusion (lyophilized powder), 0.01-2.0 mg/kg/week |
Timeline
- Start date
- 2017-03-30
- Primary completion
- 2017-10-04
- Completion
- 2017-10-04
- First posted
- 2017-04-25
- Last updated
- 2022-11-14
Locations
8 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT03128593. Inclusion in this directory is not an endorsement.